An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer

Keyphrases

• Phase II Trial 100%
• Metastatic Breast Cancer 100%
• Chemotherapy 60%
• Vascular Endothelial Growth Factor Receptor (VEGFR) 40%
• Confidence Interval 40%
• Vascular Endothelial Growth Factor 40%
• Solid Tumors 20%
• Clinical Activity 20%
• Endothelial Cells 20%
• Start of Treatment 20%
• Dyspnea 20%
• Serum Levels 20%
• Partial Response 20%
• Disease Progression 20%
• Further Development 20%
• Fever 20%
• Median Overall Survival 20%
• Adverse Events 20%
• Abdominal Pain 20%
• Safety Profile 20%
• Objective Response Rate 20%
• Plasma Parameters 20%
• Antiangiogenic 20%
• Treatment-related Adverse Events 20%
• Complete Response 20%
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 20%
• Clinical Efficacy 20%
• Subcutaneous Injection 20%
• Injection Site 20%
• Injection Site Reaction 20%
• Nausea-vomiting 20%
• 2 Receptor 20%
• Constipation 20%
• Median Progression-free Survival 20%
• Anorexia 20%
• Ribozyme 20%
• Phase 1 Study 20%
• Headache Pain 20%
• Single-arm Study 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Metastatic Breast Cancer 100%
• Angiozyme 100%
• Chemotherapy 60%
• Adverse Event 40%
• Vasculotropin 40%
• Vasculotropin Receptor 1 40%
• Solid Malignant Neoplasm 20%
• Messenger RNA 20%
• Receptor 20%
• Disease Exacerbation 20%
• Dyspnea 20%
• Overall Survival 20%
• Headache 20%
• Progression Free Survival 20%
• Antiangiogenic 20%
• Nausea and Vomiting 20%
• Vasculotropin Receptor 2 20%
• Subcutaneous Injection 20%
• Injection Site Reaction 20%
• Constipation 20%
• Abdominal Pain 20%
• Anorexia 20%
• Ribozyme 20%

Medicine and Dentistry

• Metastatic Breast Cancer 100%
• Angiozyme 100%
• Adverse Event 40%
• Vasculotropin 40%
• Vasculotropin Receptor 1 40%
• Solid Malignant Neoplasm 20%
• Messenger RNA 20%
• Headache 20%
• Dyspnea 20%
• Receptor 20%
• Arm 20%
• Endothelial Cell 20%
• Disease Exacerbation 20%
• Overall Survival 20%
• Abdominal Pain 20%
• Nausea and Vomiting 20%
• Subcutaneous Injection 20%
• Antiangiogenic 20%
• Constipation 20%
• Injection Site 20%
• Progression Free Survival 20%
• Anorexia 20%
• Vasculotropin Receptor 2 20%
• Ribozyme 20%
• Injection Site Reaction 20%